NEW YORK (360Dx) – Celcuity said after the close of the markets on Tuesday that it will work with Puma Biotechnology in a Phase II clinical trial.

As part of the deal, West Cancer Center will be the sponsor and principal investigator on the trial, which will use Celcuity's CELx HER2 Signaling Function test to evaluate the efficacy and safety of Puma Bio's Nerlynx (neratinib) and chemotherapy on patients with early-stage triple-negative breast cancer. Up to 27 patients will be part of the trial, the partners said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.